Literature DB >> 18476130

Retrospective analysis of the serologic response to the treatment of syphilis during pregnancy.

H L Galan1, J F Montalvo, J Deaver.   

Abstract

OBJECTIVE: The purpose of this study was to assess the effect of several maternal variables on the serologic response following the treatment of syphilis in pregnancy.
METHODS: A 5-year chart review identified 95 patients coded with syphilis at Hermann Hospital. Inclusion criteria were 1) serologically confirmed syphilis infection during the index pregnancy, 2) complete treatment during the index pregnancy, and 3) minimum of one follow-up rapid plasma reagin (RPR) titer. Forty-nine of 95 patients met the inclusion criteria. Treatment response was evaluated by comparing each post-treatment titer of a patient to her pretreatment titer. Each comparison was considered an "observation." Each observation was classified as either a positive response (>/=4-fold titer decline) or a negative response (<4-fold titer decline). Maternal variables assessed included 1) prior history of syphilis untreated or incompletely treated prior to the index pregnancy, 2) gestational age, 3) titer level, 4) unknown duration, 5) positive response at 1 month, 6) positive response at 2 months, 7) positive response at >3 months, and 8) race.
RESULTS: A positive response following treatment was significantly more likely if there was no prior history of syphilis or if there was a high initial RPR titer (>32). Only 33/54 (61%) observations at or greater than 3 months had a positive response.
CONCLUSIONS: Our study suggests that an absence of a history of syphilis and an initial high RPR titer are predictive of a positive response following appropriate treatment. Given the low percentage of observations with a positive response at 3 months, we speculate that we may be undertreating our pregnant patients with syphilis infection.

Entities:  

Year:  1997        PMID: 18476130      PMCID: PMC2364528          DOI: 10.1155/S1064744997000070

Source DB:  PubMed          Journal:  Infect Dis Obstet Gynecol        ISSN: 1064-7449


  12 in total

1.  Incidence of poliomyelitis in pregnancy; its relation to maternal age, parity and gestational period.

Authors:  M SIEGEL; M GREENBERG
Journal:  N Engl J Med       Date:  1955-11-17       Impact factor: 91.245

2.  Inoculation syphilis in human volunteers.

Authors:  H J MAGNUSON; E W THOMAS; S OLANSKY; B I KAPLAN; L DE MELLO; J C CUTLER
Journal:  Medicine (Baltimore)       Date:  1956-02       Impact factor: 1.889

Review 3.  Congenital syphilis: trends and recommendations for evaluation and management.

Authors:  P N Zenker; S M Berman
Journal:  Pediatr Infect Dis J       Date:  1991-07       Impact factor: 2.129

4.  Congenital syphilis--United States, 1983-1985.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1986-10-10       Impact factor: 17.586

5.  Treatment for early syphilis and reactivity of serologic tests.

Authors:  A L Schroeter; J B Lucas; E V Price; V H Falcone
Journal:  JAMA       Date:  1972-07-31       Impact factor: 56.272

6.  Viral hepatitis during pregnancy. Severity and effect on gestation.

Authors:  F Borhanmanesh; P Haghighi; K Hekmat; K Rezaizadeh; A G Ghavami
Journal:  Gastroenterology       Date:  1973-02       Impact factor: 22.682

7.  Unusual features of viral hepatitis in Accra, Ghana.

Authors:  R H Morrow; H F Smetana; F T Sai; J H Edgcomb
Journal:  Ann Intern Med       Date:  1968-06       Impact factor: 25.391

8.  Syphilis and congenital syphilis--United States, 1985-1988.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1988-08-19       Impact factor: 17.586

9.  Penicillin levels following the administration of benzathine penicillin G in pregnancy.

Authors:  L Nathan; R E Bawdon; J E Sidawi; R W Stettler; D M McIntire; G D Wendel
Journal:  Obstet Gynecol       Date:  1993-09       Impact factor: 7.661

10.  Inadequate treatment of syphilis in pregnancy.

Authors:  L Mascola; R Pelosi; C E Alexander
Journal:  Am J Obstet Gynecol       Date:  1984-12-15       Impact factor: 8.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.